Roy S. Herbst, MD, PhD
机构: Yale School of Medicine | Yale Cancer Center | Smilow Cancer Hospital at Yale-New Haven
每年引用次数
引用次数
引用: 105,712
H-指数: 146
I10-指数 : 487
出版物: 998
Circulating tumor DNA (ctDNA) to monitor treatment response and progression in patients treated with tyrosine kinase inhibitors (TKIs) and immunotherapy for EGFR-mutant non-small cell lung cancer (NSCLC).
Brian S. Henick , Sarah B. Goldberg , Azeet Narayan , Chiara Rossi
Journal of Clinical Oncology 35
1
2017
Highlights from: The 2008 Chicago Multidisciplinary Symposium in Thoracic Oncology
Aarati Ranganathan , David Lee , Sabeeha Muneer , Marissa Shrader
Clinical Lung Cancer 10 ( 1) 13 -19
2
2009
Abstracts From: The 10th International Lung Cancer Congress June 17–20, 2009; Kohala Coast, HI
David R. Gandara , Roy S. Herbst
Clinical Lung Cancer 10 ( 5) 380 -381
2009
2006 Highlights From: The Third International Association for the Study of Lung Cancer/American Society of Clinical Oncology/European Society of Medical Oncology International Conference on Molecular-Targeted Therapies in Lung Cancer Taormina, Sicily; November 2006
Aarati Ranganathan , Alex Adjei , Primo N. Lara , Roy S. Herbst
Clinical Lung Cancer 8 ( 4) 234 -241
2007
2007 Highlights from: the 12th World Conference on Lung Cancer Seoul, South Korea; September 2-6, 2007
Latha Shivakumar , David Lee , Aarati Ranganathan , David R. Gandara
Clinical Lung Cancer 8 ( 9) 526 -531
2007
JAK1/STAT3 Activation through a Proinflammatory Cytokine Pathway Leads to Resistance to Molecularly Targeted Therapy in Non–Small Cell Lung Cancer
Kazuhiko Shien , Vassiliki A. Papadimitrakopoulou , Dennis Ruder , Carmen Behrens
Molecular Cancer Therapeutics 16 ( 10) 2234 -2245
62
2017
Should chemotherapy plus immune checkpoint inhibition be the standard front-line therapy for patients with metastatic non-small cell lung cancer?
Sarah B. Goldberg , Roy S. Herbst
Cancer 124 ( 24) 4592 -4596
3
2018
The fork in the road: Waun Ki Hong, John Mendelsohn, and the reinvigoration of The University of Texas MD Anderson Cancer Center.
Fadlo R. Khuri , Roy S. Herbst
Cancer 125 ( 10) 1593 -1596
2019
In Vitro and In Vivo Assays for the Proliferative and Vascular Permeabilization Activities of Vascular Endothelial Growth Factor (VEGF) and Its Receptor
Seiji Yano , Roy S. Herbst , Sabura Sone
Lung Cancer 74 391 -398
2003
Epidermal growth factor receptor expression analysis in chemotherapy-naive patients with advanced non-small-cell lung cancer treated with gefitinib or placebo in combination with platinum-based chemotherapy.
Giuseppe Giaccone , Renee B. Iacona , Abderrahim Fandi , Mette Janas
Journal of Cancer Research and Clinical Oncology 135 ( 3) 467 -476
10
2009
Safety, Pharmacokinetics, and Efficacy of AMG 706, an Oral Multikinase Inhibitor, in Patients With Advanced Solid Tumors
Lee S. Rosen , Razelle Kurzrock , Marilyn Mulay , Andy Van Vugt
Journal of Clinical Oncology 25 ( 17) 2369 -2376
176
2007
Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non-small-cell lung cancer
John V Heymach , Bruce E Johnson , Diane Prager , Edit Csada
Journal of Clinical Oncology 25 ( 27) 4270 -4277
250
2007
Tyrosine-kinase inhibitors in oncology
Anne S. Tsao , Vassiliki Papadimitrakopoulou , Roy S. Herbst
Cambridge University Press 872 -883
2015
Phase I participants' views of quality of life and trial participation burdens.
Marlene Zichi Cohen , Jacquelyn Slomka , Rebecca D. Pentz , Anne L. Flamm
Supportive Care in Cancer 15 ( 7) 885 -890
17
2007
Antiangiogenic Tumor Therapy
Darren W. Davis , David J. McConkey , Wei Zhang , Roy S. Herbst
BioTechniques 34 ( 5) 1048 -1063
15
2003
Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study.
Glenn Liu , Hope S. Rugo , George Wilding , Teresa M. McShane
Journal of Clinical Oncology 23 ( 24) 5464 -5473
243
2005
Phase I Trial of the Oral Antiangiogenesis Agent AG-013736 in Patients With Advanced Solid Tumors: Pharmacokinetic and Clinical Results
Hope S. Rugo , Roy S. Herbst , Glenn Liu , John W. Park
Journal of Clinical Oncology 23 ( 24) 5474 -5483
550
2005
Clinical Cancer Advances 2005: Major Research Advances in Cancer Treatment, Prevention, and Screening—A Report From the American Society of Clinical Oncology
Roy S. Herbst , Dean F. Bajorin , Harry Bleiberg , Diane Blum
Journal of Clinical Oncology 24 ( 1) 190 -205
105
2006
Clinically meaningful improvement in symptoms and quality of life for patients with non-small-cell lung cancer receiving gefitinib in a randomized controlled trial.
David Cella , Roy S. Herbst , Thomas J. Lynch , Diane Prager
Journal of Clinical Oncology 23 ( 13) 2946 -2954
102
2005
Phase I/II Trial Evaluating the Anti-Vascular Endothelial Growth Factor Monoclonal Antibody Bevacizumab in Combination With the HER-1/Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib for Patients With Recurrent Non–Small-Cell Lung Cancer
Roy S. Herbst , David H. Johnson , Eric Mininberg , David P. Carbone
Journal of Clinical Oncology 23 ( 11) 2544 -2555
690
2005